[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PlaceboControl group: Injection of a placebo intramuscularly (deltoid muscle) in 100 participants in Shahid Soleimani Clinical Trial Center", "treatment_type": "TODO", "pharmacological_treatment": "Placebo"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention Group: Injection of a dose of 80 micrograms of recombinant RBD protein vaccine intramuscularly (deltoid muscle) in 10000 participants in affiliated centers of Baqiyatallah Hospital and 200 participants in Shahid Soleimani Clinical Trial Center", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "1;80 \u03bcg;who have received two identical doses of the available vaccine (Sinopharm, CovIran Barakat, AstraZenka) and at least 3 months (at least 90 days) have passed since the second dose", "treatment_id": 1920, "treatment_name": "Noora", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]